Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients

Molecular Therapy

Volumn 8, Issue 1, 2003, Pages 42-50

  Bowman, Janice E ^a   Reese, Jane S ^a   Lingas, Karen T ^a   Gerson, Stanton L ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

BCNU; Drug resistance; Gene therapy; Hematopoiesis; O6 alkylguanine DNA alkyltransferase; O6 benzylguanine

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O BENZYLGUANINE; CARMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RETROVIRUS VECTOR;

ANIMAL CELL; ARTICLE; CELL POPULATION; CELL SELECTION; CELL TRANSPLANTATION; CONTROLLED STUDY; DRUG RESISTANCE; GENE EXPRESSION; GENE MUTATION; GENE TRANSFER; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; TRANSGENE;

ANIMALIA; UNIDENTIFIED RETROVIRUS;

EID: 0043201417     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00141-2     Document Type: Article

References (35)

1. Barranger, J. A., et al. (1997). Gaucher's disease: studies of gene transfer to haematopoietic cells. Baillieres Clin. Haematol. 10: 765-778.
2. + cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum. Gene Ther. 9: 2629-2640.
3. Hanania, E. G., et al. (1996). Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc. Natl. Acad. Sci. USA 93: 15346-15351 [Published erratum appears in Proc. Natl. Acad. Sci. USA, 1997, 94: 5495].
4. Hesdorffer, C., et al. (1998). Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J. Clin. Oncol. 16: 165-172.
5. Zhao, R. C., McIvor, R. S., Griffin, J. D., and Verfaillie, C. M. (1997). Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and non-tumorigenic in vivo. Blood 90: 4687-4698.
6. Abonour, R., et al. (2000). Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat. Med. 6: 652-658.
7. Allay, J. A., et al. (1998). In vivo selection of retrovirally transduced hematopoietic stem cells. Nat. Med. 4: 1136-1143.
8. Gerson, S. (2002). Clinical relevance of MGMT in the treatment of cancer. J. Clin. Oncol. 20: 2388-2399.
9. 6 alkylguanine-DNA-alkyltransferase. Clin. Cancer Res. 7: 2309-2317.
10. Micetich, K. C., et al. (1992). Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer. J. Natl. Cancer Inst. 84: 256-260.
11. Smith, D. C., et al. (1996). Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase. Clin. Cancer Res. 2: 1129-1134.
12. 6-alkylguanine alkyltransferase-directed DNA repair in metastatic colon cancers. J. Clin. Oncol. 13: 2301-2308.
13. 6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow. Blood 89: 1566-1573.
14. 6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea. Proc. Natl. Acad. Sci. USA 93: 14088-14093.
15. 6-benzylguanine and 1,3-bis(2-chloroethyl -1-nitrosourea. Cancer Res. 57: 5093-5099.
16. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts. Hum. Gene Ther. 10: 1021-1030.
17. Jansen, M., et al. (2001). Protection of hematopoietic cells from O(6)-alkylation damage by O(6)-methylguanine DNA methyltransferase gene transfer: studies with different O(6)-alkylating agents and retroviral backbones. Eur. J. Haematol. 67: 2-13.
18. 6-benzylguanine and temozolomide. Clin. Cancer Res. 5: 163-169.
19. Davis, B. M., Koc, O. N., and Gerson, S. L. (2000). Limiting numbers of G156A O(6)-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection. Blood 95: 3078-3084.
20. 6⋯thylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy. Hum. Gene Ther. 10: 2769-2778.
21. 6-benzylguanine-resistant mutant MGMT genes improve hematopoietic cell tolerance to alkylating agents. Prog. Exp. Tumor Res. 36: 65-81.
22. Weissman, I. L., Anderson, D. J., and Gage, F. (2001). Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. Annu. Rev. Cell Dev. Biol. 17: 387-403.
23. Allay, J. A., et al. (1995). Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells. Blood 85: 3342-3351.
24. Maze, R., et al. (1996). Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. Proc. Natl. Acad. Sci. USA 93: 206-210.
25. Ragg, S., et al. (2000). Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res. 60: 5187-5195.
26. 6-methylguanine DNA methyltransferase. Bone Marrow Transplant. 25(Suppl. 2): S105-109.
27. Jandl J.H. (1987). Blood: Textbook of Hematology, Little, Brown Medical Division, Boston.
28. Abkowitz, J., Catlin, S., McCallie, M., and Guttorp, P. (2002). Evidence that the number of hematopoietic stem cells is conserved in mammals. Blood 100: 2665-2667.
29. Jordan, C. T., and Lemischka, I. R. (1990). Clonal and systemic analysis of long-term hematopoiesis in the mouse. Genes Dev. 4: 220-232.
30. Licht, T., Aksentijevich, I., Gottesman, M., and Pastan, I. (1995). Efficient expression of functional human MDR1 gene in murine bone marrow after retroviral transduction of purified hematopoietic stem cells. Blood 86: 111-121.
31. Hanania, E. G., et al. (1995). Transduction of marrow cells before transplant with retroviral vectors which contain the multidrug resistance-1 (MDR-1) cDNA is associated with long term resistance to taxol and permits in vivo selection of genetically-modified cells after transplantation. J. Invest. Med. 43: 278A.
32. McIvor, R. S. (1996). Drug-resistant dihydrofolate reductases: generation, expression and therapeutic application. Bone Marrow Transplant. 18: S50-54.
33. 6-methylguanine-DNA methyltransferase using bicistronic vectors with human multidrug resistance gene 1. Mutat. Res. 401: 133-141.
34. 6-benzylguanine. Cancer Res. 58: 1936-1945.
35. 6-alkylguanine-DNA-alkyltransferase measured by flow cytometric analysis in blood and bone marrow mononuclear cells. Clin. Cancer Res. 4: 475-481.